It was obvious that the diagnostic performance of the autoantibody panel for breast cancer was improved when compared to individual autoantibodies, of which the AUCs and sensitivities ranged from 0.721 (NY-ESO-1 autoantibody) to 0.766 (p53 autoantibody), and from 25.2% (HSP70 autoantibody) to 40.7% (p53 autoantibody), respectively. This evidence concerns the gene TP53 and breast cancer.